Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Equity Average (2016 - 2025)

Cumberland Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $25.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 7.77% year-over-year to $25.5 million; the TTM value through Dec 2025 reached $25.5 million, up 7.77%, while the annual FY2025 figure was $23.9 million, N/A changed from the prior year.
  • Equity Average for Q4 2025 was $25.5 million at Cumberland Pharmaceuticals, down from $26.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $47.3 million in Q2 2021 and bottomed at $23.7 million in Q4 2024.
  • The 5-year median for Equity Average is $36.2 million (2023), against an average of $35.0 million.
  • The largest annual shift saw Equity Average plummeted 30.34% in 2024 before it grew 7.77% in 2025.
  • A 5-year view of Equity Average shows it stood at $44.6 million in 2021, then dropped by 16.12% to $37.4 million in 2022, then decreased by 3.17% to $36.2 million in 2023, then tumbled by 34.72% to $23.7 million in 2024, then increased by 7.77% to $25.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Equity Average are $25.5 million (Q4 2025), $26.9 million (Q3 2025), and $28.0 million (Q2 2025).